Carbon

CARBON Newsletter (17 July 2026) - Your Latest News About CRISPR in AgroBio

Some of the best links we picked up around the internet

By: Gorm Palmgren - Jul. 17, 2026
News

CRISPR AgroBio News (CARBON) - an emerging initiative from CRISPR Medicine News - brings you the latest news on how CRISPR can shape agriculture for the future to guarantee food security in times of population growth and climate change.

To get more CRISPR AgroBio News delivered to your inbox, sign up to the free monthly CARBON Newsletter here.

Top picks

  • Suppressor screening identified OsSnRK1β1A as a regulator that boosts rice grain number by restricting nuclear localization of OsSnRK1α1 and suppressing energy catabolism, while OsOTUB1 keeps it in check via competitive inhibition and K63-linked deubiquitination that triggers its degradation. This OsOTUB1-OsSnRK1β1A module reallocates carbon, nitrogen, and lipid metabolism toward reproductive development, and CRISPR-Cas9 promoter editing (targeting the CAREOSREP1 and CCAAT-box elements) to upregulate OsSnRK1β1A increased yield without harming plant architecture – offering a practical route to higher-yield rice.
  • Tropic has acquired banana propagation company Rahan Meristem to accelerate global deployment of its gene-edited banana varieties. The deal integrates variety development, propagation and distribution, supporting commercial rollout of bananas with traits including disease resistance, reduced browning, extended shelf life, higher yields and resilience to threats such as Panama disease TR4. The acquisition strengthens Tropic’s capacity to scale production and grower adoption worldwide.

Technical advances

Disease and stress control

Agronomic traits

Industry

Screening

Detection

Reviews

Tags

HashtagArticleHashtagNewsHashtagCARBONHashtagCARBON NewsletterHashtagPairwise

CLINICAL TRIALS
Non-small Cell Lung Cancer, NSCLC, (NCT06097962)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Gastric Cancer and Colorectal Cancer, CRC, (NCT07166263)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.  
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory Acute Myeloid Leukemia, AML, (NCT06541444)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
Indicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine